Jim Cramer Says Treat Vaccines, Stock Market With Skepticism Monday
Jim Cramer Says Treat Vaccines, Stock Market With Skepticism Monday
Happy Monday!
周一快乐！
As of 12 P.M. ET, the Dow rose, the Nasdaq rose and the S&P rose as Wall Street was met with more positive vaccine news to kick off Thanksgiving week.
截至美国东部时间下午12点，道琼斯指数上涨，纳斯达克指数上涨，标准普尔指数上涨，华尔街迎来了更多积极的疫苗消息，拉开了感恩节周的序幕。
Referring to his previous experience navigating news around COVID testing developments, Jim Cramer said that he is approaching vaccine news and the subsequent market reaction with skepticism in his daily live show withTheStreet.
吉姆·克雷默(Jim Cramer)在谈到他之前在COVID测试进展中浏览新闻的经历时说，在他与The Street的日常直播节目中，他对疫苗新闻和随后的市场反应持怀疑态度。
As mentioned previously, Cramer is less concerned with the actual vaccines and more with how the vaccine will be rolled out to the general public when approved.
如前所述，克雷默不太关心实际的疫苗，而更关心的是疫苗在获得批准后将如何向公众推出。
Cramer said his skepticism is derived from previous positive developments that never came to fruition, such as mass testing in Walmart( WMT ) - Get Reportparking lots. "Why should I necessarily believe this vaccine is going to be distributed right," Cramer asked.
克雷默说，他的怀疑源于之前从未取得成果的积极进展，比如沃尔玛(Walmart)-Get Report停车场的大规模测试。克雷默问：“为什么我一定要相信这种疫苗会得到正确的分配。”
"Let's maintain her skepticism while at the same time...being a little more positive," Cramer said. "I just don't want people to think we're buying stocks like we're all going to have a vaccine by January."
克雷默说：“让我们保持她的怀疑态度，同时……保持积极一点。”“我只是不想让人们认为我们在买入股票，就好像我们都会在明年1月之前接种疫苗一样。”
Jim Cramer talks vaccines, Regeneron, Tesla, Merck, the presidential transition and more in the video below:
吉姆·克雷默在下面的视频中谈到了疫苗、Regeneron、特斯拉、默克、总统过渡等问题：
The COVID-19 vaccine candidate being developed by AstraZeneca( AZN ) - Get Reportand the University of Oxford was found in a large trial to have a 70% efficacy in preventing the virus. But when a half dose of the vaccine was followed by a full dose a month later it showed 90% effectiveness.
阿斯利康(AstraZeneca)和牛津大学(University Of Oxford)正在研发的新冠肺炎候选疫苗在一项大型试验中被发现具有70%的预防病毒效果。但是，当半剂疫苗在一个月后全量接种时，显示出90%的有效率。
“We see a lot of merit in this regimen and we will now start discussions with regulators into incorporating this dose combination for further clinical investigation,” said an AstraZeneca spokesman.
阿斯利康的一位发言人说：“我们看到了这种疗法的许多优点，我们现在将开始与监管机构讨论纳入这种剂量组合，以进行进一步的临床研究。”
And, over the weekend, the FDA granted approval to Regeneron( REGN ) - Get Reporttreatments casirivimab and imdevimab, which the agency said can now be given together to treat mild to moderate disease in people older than age 12.
上周末，FDA批准了Regeneron(REGN)-Get Report Treatment casirivimab和imdemab，该机构表示，这两种药物现在可以一起用于治疗12岁以上人群的轻中度疾病。
A clinical trial of patients infected with the coronavirus showed that casirivimab and imdevimab, when given together and administered via intravenous infusion, cut down Covid-19-related hospitalizations in high-risk patients within 28 days after treatment when compared to placebo, according to FDA.
根据美国食品和药物管理局的说法，一项对感染冠状病毒的患者的临床试验表明，与安慰剂相比，卡西维玛和伊莫司马联合使用并通过静脉输注的方式，可以减少高危患者在治疗后28天内因新冠肺炎而住院的次数。
While Cramer said Regeneron "has something great," he remains concerned about the ability for the company to manufacture the treatment at scale. "I very much believe in Regeneron; it's an incredible company, but can we get it at scale," Cramer asked.
虽然克雷默说Regeneron“有很好的东西”，但他仍然担心该公司规模化生产治疗的能力。克雷默问道：“我非常相信Regeneron；这是一家令人难以置信的公司，但我们能规模化吗？”
Daniel Kuhn contributed reporting to this article. Latest Videos From TheStreet and Jim Cramer:
丹尼尔·库恩(Daniel Kuhn)对本文也有贡献。来自TheStreet和Jim Cramer的最新视频：
AstraZeneca, Oxford Say Phase 2 Shows Immune Response: Latest on Race to COVID VaccineJim Cramer Gives Investors Two Unique Stock Pick IdeasBest Black Friday Deals: WalletHub's Top 10 RetailersJim Cramer: How to Balance Stay-At-Home and Return to Normal Plays
阿斯利康，牛津说，第二阶段显示出免疫反应：最新的COVID疫苗竞赛吉姆·克雷默给投资者两个独特的选股想法最佳黑色星期五交易：WalletHub的十大零售商吉姆·克雷默：如何平衡呆在家里和回归正常
译文内容由第三方软件翻译。